Patents by Inventor Jay G. Calvert

Jay G. Calvert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11911454
    Abstract: The invention provides isolated polynucleotide molecules that comprise a DNA sequence encoding an infectious RNA sequence encoding a genetically-modified North American PRRS virus, methods to make it and related polypeptides, polynucleotides, and various components. Vaccines comprising the genetically modified virus and polynucleotides and a diagnostic kit to distinguish between naturally infected and vaccinated animals are also provided.
    Type: Grant
    Filed: June 6, 2022
    Date of Patent: February 27, 2024
    Assignee: Zoetis Services LLC
    Inventors: Jay Gregory Calvert, Robert G. Ankenbauer, Jacqueline Gayle Marx, Douglas S. Pearce, Marcia L. Keith
  • Patent number: 8492132
    Abstract: The invention provides isolated polynucleotide molecules, plasmids, viral vectors, and transfected host cells that comprise a DNA molecule encoding an infectious RNA molecule that encode a PRRS (Porcine Reproductive and Respiratory Syndrome) virus, and further provides the PRRS virus encoded thereby. The invention also provides isolated infectious RNA molecules encoding PRRS virus.
    Type: Grant
    Filed: October 28, 2009
    Date of Patent: July 23, 2013
    Assignee: Zoetis LLC
    Inventors: Jay G. Calvert, Michael G. Shepard, Siao-Kun W. Welch
  • Publication number: 20110150913
    Abstract: The present invention is directed to novel nucleotide and amino acid sequences of Torque teno virus (“TTV”), including novel genotypes thereof, all of which are useful in the preparation of vaccines for treating and preventing diseases in swine and other animals. Vaccines provided according to the practice of the invention are effective against multiple swine TTV genotypes and isolates. Diagnostic and therapeutic polyclonal and monoclonal antibodies are also a feature of the present invention, as are infectious clones useful in the propagation of the virus and in the preparation of vaccines. Particularly important aspects of the invention include vaccines that provide TTV ORF1 protein, or peptide fragments thereof, as antigen.
    Type: Application
    Filed: October 16, 2009
    Publication date: June 23, 2011
    Inventors: Gregory P. Nitzel, Mira I Stoeva, James R. Thompson, Nancee L. Oien, Jay G. Calvert, Donna Steuerwald Dunyak, Jacqueline Gayle Mark, Robert Gerard Ankenbauer, Douglas Steven Pearce
  • Patent number: 7232680
    Abstract: The invention provides isolated polynucleotide molecules, including plasmids; viral vectors; and transfected host cells that comprise a DNA sequence encoding an infectious RNA sequence encoding a North American PRRS virus; and also North American PRRS viruses encoded thereby. The invention further provides isolated infectious RNA molecules encoding a North American PRRS virus. The invention also provides isolated polynucleotide molecules, infectious RNA molecules, viral vectors, and transfected host cells encoding genetically-modified North American PRRS viruses; and genetically-modified North American PRRS viruses encoded thereby. The invention also provides vaccines comprising such plasmids, RNA molecules, viral vectors, and North American PRRS viruses, and methods of using these vaccines in swine and in other animals. Also provided are isolated polynucleotide molecules, viral vectors, and transfected host cells that comprise a nucleotide sequence encoding a peptide of a North American PRRS virus.
    Type: Grant
    Filed: April 22, 2002
    Date of Patent: June 19, 2007
    Assignee: Pfizer Inc.
    Inventors: Jay G. Calvert, Michael G. Sheppard, Siao-Kun W. Welch
  • Patent number: 7132106
    Abstract: The invention provides isolated polynucleotide molecules, including plasmids; viral vectors; and transfected host cells that comprise a DNA sequence encoding an infectious RNA sequence encoding a North American PRRS virus; and also North American PRRS viruses encoded thereby. The invention further provides isolated infectious RNA molecules encoding a North American PRRS virus. The invention also provides isolated polynucleotide molecules, infectious RNA molecules, viral vectors, and transfected host cells encoding genetically-modified North American PRRS viruses; and genetically-modified North American PRRS viruses encoded thereby. The invention also provides vaccines comprising such plasmids, RNA molecules, viral vectors, and North American PRRS viruses, and methods of using these vaccines in swine and in other animals. Also provided are isolated polynucleotide molecules, viral vectors, and transfected host cells that comprise a nucleotide sequence encoding a peptide of a North American PRRS virus.
    Type: Grant
    Filed: September 11, 2002
    Date of Patent: November 7, 2006
    Assignee: Pfizer Inc.
    Inventors: Jay G. Calvert, Michael G. Sheppard, Siao-Kun W. Welch
  • Publication number: 20030157689
    Abstract: The invention provides isolated polynucleotide molecules, including plasmids; viral vectors; and transfected host cells that comprise a DNA sequence encoding an infectious RNA sequence encoding a North American PRRS virus; and also North American PRRS viruses encoded thereby. The invention further provides isolated infectious RNA molecules encoding a North American PRRS virus. The invention also provides isolated polynucleotide molecules, infectious RNA molecules, viral vectors, and transfected host cells encoding genetically-modified North American PRRS viruses; and genetically-modified North American PRRS viruses encoded thereby. The invention also provides vaccines comprising such plasmids, RNA molecules, viral vectors, and North American PRRS viruses, and methods of using these vaccines in swine and in other animals. Also provided are isolated polynucleotide molecules, viral vectors, and transfected host cells that comprise a nucleotide sequence encoding a peptide of a North American PRRS virus.
    Type: Application
    Filed: September 11, 2002
    Publication date: August 21, 2003
    Inventors: Jay G. Calvert, Michael G. Sheppard, Siao-Kun W. Welch
  • Patent number: 6500662
    Abstract: The invention provides isolated polynucleotide molecules, including plasmids; viral vectors; and transfected host cells that comprise a DNA sequence encoding an infectious RNA sequence encoding a North American PRRS virus; and also North American PRRS viruses encoded thereby. The invention further provides isolated infectious RNA molecules encoding a North American PRRS virus. The invention also provides isolated polynucleotide molecules, infectious RNA molecules, viral vectors, and transfected host cells encoding genetically-modified North American PRRS viruses; and genetically-modified North American PRRS viruses encoded thereby. The invention also provides vaccines comprising such plasmids, RNA molecules, viral vectors, and North American PRRS viruses, and methods of using these vaccines in swine and in other animals. Also provided are isolated polynucleotide molecules, viral vectors, and transfected host cells that comprise a nucleotide sequence encoding a peptide of a North American PRRS virus.
    Type: Grant
    Filed: December 22, 1999
    Date of Patent: December 31, 2002
    Assignee: Pfizer Inc.
    Inventors: Jay G. Calvert, Michael G. Sheppard, Siao-Kun W. Welch
  • Publication number: 20020172690
    Abstract: The invention provides isolated polynucleotide molecules, including plasmids; viral vectors; and transfected host cells that comprise a DNA sequence encoding an infectious RNA sequence encoding a North American PRRS virus; and also North American PRRS viruses encoded thereby. The invention further provides isolated infectious RNA molecules encoding a North American PRRS virus. The invention also provides isolated polynucleotide molecules, infectious RNA molecules, viral vectors, and transfected host cells encoding genetically-modified North American PRRS viruses; and genetically-modified North American PRRS viruses encoded thereby. The invention also provides vaccines comprising such plasmids, RNA molecules, viral vectors, and North American PRRS viruses, and methods of using these vaccines in swine and in other animals. Also provided are isolated polynucleotide molecules, viral vectors, and transfected host cells that comprise a nucleotide sequence encoding a peptide of a North American PRRS virus.
    Type: Application
    Filed: April 22, 2002
    Publication date: November 21, 2002
    Inventors: Jay G. Calvert, Michael G. Sheppard, Siao-Kun W. Welch
  • Patent number: 5403582
    Abstract: A recombinant fowlpox virus is provided which is useful as a vaccine for protection against avian reticuloendo-theliosis virus-associated diseases. In a specific embodiment, the recombinant virus expresses a gene encoding an envelope glycoprotein of spleen necrosis virus under the control of a poxvirus promoter, inserted in a nonessential region of the fowlpox virus genome.
    Type: Grant
    Filed: January 21, 1993
    Date of Patent: April 4, 1995
    Assignees: Nippon Zeon Co., Ltd., The United States of America as represented by the Secretary of Agriculture
    Inventors: Keyvan Nazerian, Jay G. Calvert, Richard L. Witter, Noboru Yanagida